Cytotoxicity, Immunologic

• 

  Subject Areas on Research

  • 1 alpha,25 Dihydroxyvitamin D3 and mononuclear phagocytes: enhancement of mouse macrophage and human monocyte hydrogen peroxide production without alteration of tumor cytolysis. 
  • 2B4 utilizes ITAM-containing receptor complexes to initiate intracellular signaling and cytolysis. 
  • A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. 
  • A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. 
  • A cytotoxic proteinase isolated from human lymphocytes. 
  • A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. 
  • A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. 
  • A monoclonal antibody reactive with a second epitope of the 67,000-dalton human T cell antigen. 
  • A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. 
  • A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. 
  • Abrogation of baboon natural xenoantibody to pig splenocytes by DL-penicillamine. 
  • Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. 
  • Activated lymphocytes promote endothelial cell detachment from matrix: a role for modulation of endothelial cell beta 1 integrin affinity. 
  • Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. 
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. 
  • Age-related development of human anti-pig xenoantibody. 
  • Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. 
  • Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. 
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. 
  • Anti-self HLA may be clonally expressed. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. 
  • Association of chronic thromboxane inhibition with reduced in situ cytotoxic T cell activity in rejecting rat renal allografts. 
  • Astrocyte cytolysis by MHC class II-specific mouse T cell clones. 
  • Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • B cell-ablative therapy for the treatment of autoimmune diseases. 
  • CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. 
  • CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. 
  • CD8(+)NKR-P1A (+)T cells preferentially accumulate in human liver. 
  • CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. 
  • Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. 
  • Carbohydrate changes in pre- and peri-implantation mouse embryos as detected by a monoclonal antibody. 
  • Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. 
  • Cell surface F1Fo ATP synthase: a new paradigm? 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Cell-mediated cytotoxicity of murine cytomegalovirus-infected target cells allows for release of residual infectious virus. 
  • Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. 
  • Cellular immune response to cryptic epitopes during therapeutic gene transfer. 
  • Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity. 
  • Characterization of T cells expressing the gamma/delta antigen receptor in human renal allografts. 
  • Characterization of cytotoxic cells generated from in vitro cultures of murine bone marrow cells. 
  • Characterization of the effects of endotoxin on macrophage tumor cell killing. 
  • Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype. 
  • Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. 
  • Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. 
  • Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. 
  • Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Combined total lymphoid irradiation and cyclosporine promote xenograft survival. 
  • Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. 
  • Comparison of the relative cytotoxic effector cell capabilities and the proportions of cells bearing various surface markers in human tonsil and peripheral blood mononuclear cells. 
  • Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cells. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. 
  • Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. 
  • Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity. 
  • DNA array-based gene profiling in tumor immunology. 
  • Defective antitumor responses in CX3CR1-deficient mice. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. 
  • Depletion of passenger leukocytes from corneal grafts: an effective means of promoting transplant survival? 
  • Detection of pyroptosis by measuring released lactate dehydrogenase activity. 
  • Differential requirements for NAIP5 in activation of the NLRC4 inflammasome. 
  • Discordant complement systems as a factor in hyperacute xenograft rejection. 
  • Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. 
  • Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. 
  • Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. 
  • Effects of oxidized LDL on mononuclear phagocytes: inhibition of induction of four inflammatory cytokine gene RNAs, release of NO, and cytolysis of tumor cells. 
  • Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. 
  • Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. 
  • Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. 
  • Enhancement of macrophage-mediated tumor cell killing by bacterial outer membrane proteins (porins). 
  • Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. 
  • Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. 
  • Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. 
  • Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma. 
  • Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants. 
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. 
  • Functional alterations of macrophages in autoimmune MRL-lpr/lpr mice. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. 
  • Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. 
  • Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. 
  • Graft hyporeactivity induced by donor-derived dendritic cell progenitors. 
  • Graft-versus-host disease: the viewpoint from the donor T cell. 
  • HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes. 
  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. 
  • Hapten-specific T cell response to 4-hydroxy-3-nitrophenyl acetyl. X. Characterization of distinct T cell subsets mediating cutaneous sensitivity responses. 
  • Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. 
  • Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. 
  • Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. 
  • Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • IFN-gamma production in response to neuropathogenic Cas-Br-M murine leukemia virus infection. 
  • Identification and functional analysis of human natural anti-pig xenoantibodies. 
  • Identification of a tumor associated antigen that can induce tumor specific cytotoxicity. 
  • Immune responses of human lymphocytes in vitro. 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Immunogenic determinants of a neuropathogenic murine leukemia virus. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction. 
  • Immunologic targeting of FOXP3 in inflammatory breast cancer cells. 
  • Immunological memory induced by genetically transduced tumor cells. 
  • Immunology. Outwitted by viral RNAs. 
  • Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. 
  • Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Implications of leukoregulin to autologous tumor-specific human T-cell populations. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • In situ and systemic cellular immunity associated with orthotopic rat liver allograft acceptance or rejection. 
  • In vitro function of indium-111 oxine-labeled human monocytes. 
  • In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. 
  • In vitro modulation of macrophage tumoricidal activity: partial characterization of a macrophage-activating factor(s) in supernatants of NaIO4-treated peritoneal cells. 
  • In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice. 
  • In vivo modulation of macrophage tumoricidal activity: enhanced tumor cell killing by peritoneal macrophages from mice given injections of sodium periodate. 
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. 
  • Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. 
  • Induction of protective CTL responses in newborn mice by a murine retrovirus. 
  • Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. 
  • Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. 
  • Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells. 
  • Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages. 
  • Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. 
  • Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity. 
  • Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. 
  • Leishmania species: mechanisms of complement activation by five strains of promastigotes. 
  • Leukocyte composition of human breast cancer. 
  • Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. 
  • Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance. 
  • Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity. 
  • Lymphokine-activated killer cell activity after cryopreservation. 
  • Lyt phenotype of H-2b CTL effectors and precursors specific for the SV40 transplantation rejection antigen. 
  • M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. 
  • Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. 
  • Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. 
  • Mechanisms of inflammation and leukocyte chemotaxis in the rheumatic diseases. 
  • Mechanisms of the antioxidant effects of nitric oxide. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. 
  • Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. 
  • Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin. 
  • Modulation of the tumoricidal function of activated macrophages by bacterial endotoxin and mammalian macrophage activation factor (s). 
  • Monensin enhances the cytotoxic effect of antitransferrin receptor immunotoxin on cultured RPE cells. 
  • Monolayer absorption of human cytotoxic T cells: evidence for clonality. 
  • Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. 
  • Murine in vitro antigenic modification of tumor cells: effect on susceptibility to natural cell-mediated cytotoxicity. 
  • NK and LAK susceptibility varies inversely with target cell MHC class I antigen expression in a rat epithelial tumour system. 
  • NK susceptibility varies inversely with target cell class I HLA antigen expression. 
  • NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. 
  • NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. 
  • Natural antipig xenoantibody is absent in neonatal human serum. 
  • Natural killer cell infection and inactivation in vitro by the human immunodeficiency virus. 
  • Natural killer cell-endothelial cell interactions in xenotransplantation. 
  • Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. 
  • Neonate-primed CD8+ memory cells rival adult-primed memory cells in antigen-driven expansion and anti-viral protection. 
  • Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. 
  • New approaches to HIV vaccine development. 
  • Newborn baboon serum anti-alpha galactosyl antibody levels and cytotoxicity to cultured pig kidney (PK15) cells. 
  • Noncytolytic CD8 T cell-mediated suppression of HIV replication. 
  • Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. 
  • Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. 
  • Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. 
  • Orphan nuclear receptors in T lymphocyte development. 
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. 
  • Perforin knockout mice, but not mice with MAIDS, show protection against experimental cytomegalovirus retinitis after adoptive transfer of immune cells with a functional perforin cytotoxic pathway. 
  • Phagocytosis and killing of Cryptococcus neoformans by rat alveolar macrophages in the absence of serum. 
  • Phase I studies of recombinant interferon-gamma. 
  • Phenotype and function of T cells propagated from donor-specific blood transfusion enhanced and autologous blood transfused rejecting rat renal allografts. 
  • Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. 
  • Phenotypic characterization of human bone marrow granulocyte-macrophage forming progenitor cells. 
  • Phenotypic characterization of human cytolytic T lymphocytes in mixed lymphocyte culture. 
  • Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. 
  • Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. 
  • Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. 
  • Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon. 
  • Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. 
  • Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line. 
  • Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. 
  • Recombinant leukocyte A interferon for the treatment of serious viral infections after marrow transplant: a phase I study. 
  • Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. 
  • Relationship between sensitivity to natural killer cells and MHC class-I antigen expression in colon carcinoma cell lines. 
  • Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. 
  • Retinoic acid modulation of alpha(1-->2) fucosyltransferase activity and sensitivity of tumor cells to LAK-mediated cytotoxicity. 
  • Role for hedgehog pathway in regulating growth and function of invariant NKT cells. 
  • Role of LAT in the granule-mediated cytotoxicity of CD8 T cells. 
  • Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. 
  • Season and size of urban particulate matter differentially affect cytotoxicity and human immune responses to Mycobacterium tuberculosis. 
  • Selective inhibition of natural killer activity by the monoclonal antibodies OKT10 and VEP10 at the single cell level. 
  • Self-discrepancy and natural killer cell activity: immunological consequences of negative self-evaluation. 
  • Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. 
  • Silencing porcine genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation. 
  • Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. 
  • Spontaneous tumor cell killing by human blood monocytes and human peritoneal macrophages: lack of alteration by endotoxin or quenchers of reactive oxygen species. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. 
  • T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control. 
  • TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. 
  • The antiapoptotic protein Bcl-xL is dispensable for the development of effector and memory T lymphocytes. 
  • The effect of 15-deoxyspergualin on hamster-to-rat cardiac xenograft survival. 
  • The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. 
  • The effects of donor-specific blood transfusion enhancement of rat renal allografts on cytotoxic activity and phenotypes of peripheral blood lymphocytes, splenocytes, and graft-infiltrating cells. 
  • The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice. 
  • The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. 
  • The immunologic constant of rejection. 
  • The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. 
  • The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors. 
  • The macrophage as an antineoplastic surveillance cell: biological perspectives. 
  • The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. 
  • The role of transmethylation reactions in regulating the binding of BCG-activated murine macrophages to neoplastic target cells. 
  • The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. 
  • The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. 
  • Tumor cell killing by phorbol ester--differentiated human leukemia cells. 
  • Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. 
  • Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. 
  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. 
  • Ultraviolet light exposure suppresses contact hypersensitivity by abrogating endothelial intercellular adhesion molecule-1 up-regulation at the elicitation site. 
  • Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. 
  • Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. 
  • Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. 
  • Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Virus-immune cytotoxic T cells recognize structural differences between serologically indistinguishable HLA-A2 molecules. 
  • XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells. 
• 

  Keywords of People

  • Cianciolo, George James, Associate Professor in Pathology, Pathology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Immunology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Shinohara, Mari L., Associate Professor of Immunology, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology
  • Zennadi, Rahima, Associate Professor in Medicine, Pathology
  • Zhong, Pei, Professor in the Department of Mechanical Engineering and Materials Science, Mechanical Engineering and Materials Science